Regulatory Issues in Genetic Testing and Targeted Drug Development
|
|
- Susanna Simmons
- 1 years ago
- Views:
Transcription
1 Regulatory Issues in Genetic Testing and Targeted Drug Development Janet Woodcock, M.D. Deputy Commissioner for Operations Food and Drug Administration October 12, 2006
2 Genetic and Genomic Tests are Types of Biomarkers Biomarker: a measurable characteristic that reflects physiologic or pathologic processes or states, or responses to pharmacologic interventions Genetic or genomic biomarkers: characteristics of an individual s genes or gene expression
3 Biomarker Measurement is the Foundation of Medicine Early biomarkers were physical signs and symptoms that could be measured by observation Later biomarkers (e.g., cholesterol) could provide rough prognostic information for the individual or diagnose serious organ malfunction (e.g., ECG, serum creatinine) A new generation of biomarkers that can transform diagnosis is under development: these include genetic-based assays but the universe is much broader
4 Challenges in Biomarker Development Many candidate biomarkers are discovered Few are evaluated rigorously for their clinical implications i.e., what they really mean in terms of human health A number enter clinical use but fewer receive regulatory acceptance (e.g., for use in drug development) and reimbursement is uneven
5 Reasons for Lagging Development of Clinical Biomarkers Lack of good business models for diagnostics Difficulty in establishing clinical correlation: what is needed? Clinical community focus on intervention vs diagnosis e.g., reimbursement practices Until recently: not so many good candidates
6 FDA's Critical Path Initiative A serious attempt to bring attention and focus to the need for targeted scientific efforts to modernize the processes and methods used to evaluate the safety, efficacy and quality of medical products as they move from product selection and design to mass manufacture.
7 What is the Critical Path? There is a critical path stretching from candidate identification to commercial product Involves serial evaluation of product performance through preclinical testing and clinical evaluation The science underlying the critical path has lagged behind the progress of other biomedical science FDA s Critical Path Initiative focuses on improving the science used for these evaluations
8 The Critical Path for Medical Product Development Is Now the Bottleneck
9 Evaluative Science Underlying The Critical Path Science to predict and evaluate safety & efficacy performance of new products, and enable manufacture, is different from basic discovery science
10 "Critical Path Dimensions Evaluative science to address 3 key product performance dimensions: Assessment of Safety how to predict and asses the risks of a potential product? Proof of Efficacy -- how to predict and demonstrate that a potential product will have medical benefit? Industrialization how to manufacture a product at commercial scale with consistently high quality?
11 Steps to Date Published Initial Report: Innovation or Stagnation, 5/04 Opened Docket; numerous public discussions about drug, device and biologic development challenges Initiating multiple public-private partnership consortia with non-profit conveners Published Critical Path Opportunities Report and List 3/06
12 Major Opportunities for Modernization per Critical Path Opportunities List Biomarker Qualification In-vitro diagnostics Imaging Preclinical toxicogenomics Clinical Trial Modernization Bioinformatics Modernizing Manufacturing Pediatric Treatments Public Health Emergencies
13 Genetic Tests and FDA s Critical Path Initiative Major opportunity: Utilize new biomarkers to modernize product development Genetic/genomic markers prominent Proposal: Qualify biomarkers for regulatory use via public-private partnership consortia to overcome the identified obstacles
14 Progress in Biomarker Qualification Predictive Safety Consortium: Sponsored by C-Path Institute, Tucson, AZ. Developing safety biomarkers for organ toxicity using animal models hope to move into human evaluations after animal qualification C-Path also evaluating pharmacogeneticdirected dosing of warfarin Oncology Biomarker Qualification Initiative (FDA/NCI/CMS): Qualifying imaging, genetic, genomic and other biomarkers for use in cancer treatment
15 The Biomarker Consortium Announced last week Convened by FNIH: NIH/FDA/CMS; PhRMA/BIO; Nonprofit patient groups Goal: Development and Qualification of new human biomarkers Announced projects include imaging; serum protein and genetic biomarkers
16 Genetic Biomarkers and the FDA: Current Issues FDA regulation of genetic and genomic tests Use of genetic and genomic testing in therapeutic product development
17 FDA Regulation of Genetic and Genomic Tests New FDA Guidances: Testing of leftover specimens Regulation of home brew and ASRs New draft guidance on IVDMIA s
18 New FDA Guidance Documents Guidance on Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not Individually Identifiable Commercially Distributed Analyte Specific Reagents (ASRs): Frequently Asked Questions (Draft) In Vitro Diagnostic Multivariate Index Assays (Draft)
19 Leftover Specimens FDA law and regulations make patient samples subject to human subject protections and requirement for informed consent Differs from NIH Common Rule Means unidentified left-over discard samples and specimens cannot be used for development or research on new tests for FDA submissions
20 Leftover Specimens FDA intends to exercise enforcement discretion, under certain circumstances, with respect to requiring informed consent when human specimens are used in FDAregulated IVD Device investigations Guidance is first step regulation to follow
21 Leftover Specimens: Enforcement Discretion Investigation meets the IDE exemption criteria at 21 CFR (c)(3) The study uses leftover specimens Specimens may be coded but not individually identifiable Specimen may be accompanied by clinical information if source not identifiable Individuals caring for patients are different from those conducting the study Supplier of specimen has established policies and procedures to prevent release of identifiable information Study protocol must be reviewed by an IRB
22 ASR Draft Guidance Intended to address confusion in the marketplace and to clarify the regulations regarding commercially distributed ASRs and the role and responsibilities of ASR manufacturers Guidance was adapted from a document submitted to FDA by AdvaMed
23 ASR Guidance Intended to clarify the definition of an ASR Intended to communicate limitations on marketing of ASRs Not intended to eliminate legitimate home brew testing 90 day comment period
24 ASR Guidance Examples of ASRs: a single antibody e.g., an anti-troponin I antibody a single nucleotide primer e.g., a forward primer for amplification of the ΔF508 locus of the CFTR gene a single purified protein or peptide e.g., purified estrogen receptor protein
25 Multivariate Draft Guidance Identifies a class of laboratory developed devices subject to FDA regulation In Vitro Diagnostic Multivariate Index Assays: IVDMIAs
26 Multivariate Guidance IVDMIAs: Use clinical data (from one or more IVDs assays and sometimes demographic data) to empirically identify an algorithm Employ the algorithm to integrate these different data points in order to calculate a patient-specific result (e.g., a classification, score, or index ) The result cannot be interpreted by clinicians using prior knowledge of medicine without information from the test developer regarding its clinical performance and effectiveness
27 Multivariate Guidance IVDMIAs are a narrow niche of laboratory developed devices that are not subject to enforcement discretion Guidance indicates regulation will be risk-based by intended use (same as all other medical devices) 90 day comment period: draft has generated some confusion
28 Genetic Tests and Therapeutic Product Development Voluntary Genomic Data Submission Use in targeted therapy Drug-Diagnostic Co-development Guidance
29 Voluntary Genomic Data Submission Process FDA procedure to evaluate emerging genetic or genomic data relevant to investigational products outside the regulatory arena Enthusiastic participation by industry multiple types of genetic data shared (e.g., prognostic, patient stratification, adverse events etc) FDA able to develop expertise to evaluate proposals for standard drug development FDA also working on microarray standards via MAQC consortium (FDA s NCTR)
30 Use of Genomic Markers to Target Therapy Pharmacogenomic markers Proper dosing: Drug metabolism polymorphisms: avoiding serious side effects first tests have been approved Improving efficacy: Predictors of drug response or nonresponse (to target treated population) Improving safety: Genetic basis of adverse events avoid treating those at risk prevention is preferable to warnings
31 The Current Clinical Development Model The randomized controlled clinical trial represented a scientific triumph over anecdotal medicine in the 1960s Used to control for bias and the impact of random (unexplainable) variability but this variability is a the heart of personalization Basis for many of the advances of modern medicine
32 Limitations of Controlled Trials Theoretically can answer any and all questions via controlled experiments Can answer one or a few questions per trial There are an unlimited number of questions about the appropriate use of medical products and the outcomes of such use, and these questions evolve over time There is a decidedly limited universe of funding, patients, investigators, time and resources to conduct trials to answer these questions
33 Limitations of Controlled Trials Fact: at the end of most drug development programs, after huge expenditures of time and resources, we don t know a great deal about the drug We re quite confident it has a measurable beneficial effect in a described population-but the overall treatment effect is often small. Did few people respond a lot or did a lot of people respond a bit? Often many of the people who take the drug do not benefit
34 Limitations of Controlled Trials as Currently Conducted Binary outcome success or failure-- determined by p value limits information gain and often results in misinterpretation of data (e.g., estrogen trials) Large time expenditure and may find out at the end that the wrong question was being asked Little flexibility
35 Healthcare Consequences of Current Development Health care cost controversy: Debates about value of products: we can t quantify Health care policy community believes that increased technology=greater expense, and usually lower productivity Safety controversies: Products are Safe or Unsafe Health care quality: Confusing results and conflicting reports lead to anecdotal approach to care
36 More Informative Clinical Trial Designs Pair diagnostic(s) with therapeutic in development to identify responsive subgroup(s), or prevent toxicity Adaptive designs to answer series of questions i.e, what dose is correct for which group
37 Critical Path Payoff for Development Process More predictable process; higher success rate, lower development costs More information about product performance Continuous improvement of development science and processes
38 Critical Path: Payoff for Patients: More Personalized Treatment Much larger treatment effects via more targeted therapy Stopping ineffective therapy faster Avoidance of side effects and injury through prevention Better/earlier product availability Higher quality healthcare
39 Drug-Diagnostic Co-Development Guidance Need clear regulatory pathway for developing a investigational genetic or genomic test along with an investigational therapy Issues of sequencing, trial design, and statistical analysis important Also must clarify claims that would be allowed under various scenarios Much progress made although guidance not out yet
40 Summary FDA regulation of genetic tests remains a somewhat controversial area New draft guidances to provide greater clarity FDA is intensifying involvement in development of genetic/genomic markers Standardization of platforms for analysis is a key issue that is currently being addressed Critical Path Initiative brings intense focus on genetic/genomic biomarkers that may be used in drug development
Guidance for Sponsors, Institutional Review Boards, Clinical Investigators and FDA Staff
Guidance for Sponsors, Institutional Review Boards, Clinical Investigators and FDA Staff Guidance on Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not
In vitro Device Regulation
In vitro Device Regulation Molecular Pathologists Reagent (Analyte) Manufacturers High Complexity Clinical Labs Commercial Academic in Vitro Diagnostics Manufacturers Drug Developers large & small 2 States
FDA Regulation of Genetic Tests. Steven Gutman, M.D. Office of In Vitro Diagnostics
FDA Regulation of Genetic Tests Steven Gutman, M.D. Office of In Vitro Diagnostics Medical Device Amendments of 1976 General controls Registration and listing Good manufacturing practices Adverse event
A leader in the development and application of information technology to prevent and treat disease.
A leader in the development and application of information technology to prevent and treat disease. About MOLECULAR HEALTH Molecular Health was founded in 2004 with the vision of changing healthcare. Today
Voluntary Genomic Data Submissions at the U.S. FDA
Voluntary Genomic Data Submissions at the U.S. FDA International Conference on Harmonization Chicago, IL November 9-10, 9 2005 Felix W. Frueh, PhD Associate Director for Genomics Office of Clinical Pharmacology
A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations
A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations Ce3, Inc. and Insight Genetics, Inc. Oncology Forum July 15, 2015 Agenda Introductions Definitions Regulations
Overview of Phase 1 Oncology Trials of Biologic Therapeutics
Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of
Achieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013
Achieving Regulatory Success: Areas of focus for biotechnology companies Michael J. Schlosser, PhD, DABT April 21, 2013 Regulatory Success Outline Regulatory Initiatives Regulatory Science Pre-Regulatory
IDE Requirements for Diagnostic Tests Used in Clinical Trials
IDE Requirements for Diagnostic Tests Used in Clinical Trials J. Milburn Jessup, MD Diagnostics Evaluation Branch Cancer Diagnosis Program DCTD, NCI, NIH jessupj@mail.nih.gov Outline Background Uses of
exactly. The need for efficiency in developing effective new therapeutics has never been greater.
exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,
Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
Current Topics in the Development and Regulatory Approval of Cancer Therapies
Current Topics in the Development and Regulatory Approval of Cancer Therapies Michelle Ponpipom Associate Director Worldwide Regulatory Affairs Merck & Co., Inc. Oncology Drug Development: Dynamic & Evolving
Personalized Medicine Issues affecting adoption of personalized medicine
Personalized Medicine Issues affecting adoption of personalized medicine Introduction Personalized medicine offers a new paradigm for the development of drugs and the practice of medicine. While the potential
Roche Position on Human Stem Cells
Roche Position on Human Stem Cells Background Stem cells and treating diseases. Stem cells and their applications offer an enormous potential for the treatment and even the cure of diseases, along with
Guidance for Industry and FDA Staff Commercially Distributed Analyte Specific Reagents (ASRs): Frequently Asked Questions
Guidance for Industry and FDA Staff Commercially Distributed Analyte Specific Reagents (ASRs): Frequently Asked Questions Document issued on: September 14, 2007 The draft of this guidance document was
The Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-
Is it time for a new drug development paradigm?
Is it time for a new drug development paradigm? Robert McDonough, M.D. Senior Director, Clinical Policy Research and Development 1 The Aetna Way Our Cause To make quality health care more affordable and
The Molecular Diagnostic Market and development of personalized molecular tests
The Molecular Diagnostic Market and development of personalized molecular tests Dr. Iris Simon Sr. Director Research & Development, Agendia NV, Amsterdam NL and Irvine CA Agendia - Who are we Molecular
Call 2014: High throughput screening of therapeutic molecules and rare diseases
Call 2014: High throughput screening of therapeutic molecules and rare diseases The second call High throughput screening of therapeutic molecules and rare diseases launched by the French Foundation for
Not All Clinical Trials Are Created Equal Understanding the Different Phases
Not All Clinical Trials Are Created Equal Understanding the Different Phases This chapter will help you understand the differences between the various clinical trial phases and how these differences impact
The Retrospective Approach To Companion Diagnostics
Portfolio Media. Inc. 860 Broadway, 6th Floor New York, NY 10003 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com The Retrospective Approach To Companion Diagnostics
Division of Bioinformatics and Biostatistics
Division of Bioinformatics and Biostatistics Weida Tong, Ph.D. The views presented do not necessarily reflect the views of the FDA. 1 Established on May 20 th, 2012. Three Branches: Division Overview Bioinformatics
The Evolving Role of Nurses in Early Phase Research
U.S. Department of Health and Human Services The Evolving Role of Nurses in Early Phase Research Clare Hastings, RN, PhD, FAAN Chief Nurse Officer, Clinical Center April 27, 2012 Discover America s Research
Cancer Clinical Trials: In-Depth Information
Cancer Clinical Trials: In-Depth Information The Drug Development and Approval Process 1. Early research and preclinical testing 2. IND application filed with FDA 3. Clinical trials (phases 1, 2, and 3)
Human Research Protection Program University of California, San Diego ISSUES ON DNA AND INFORMED CONSENT
Human Research Protection Program University of California, San Diego ISSUES ON DNA AND INFORMED CONSENT Regulatory changes will occur for investigators studying human DNA The recent acceleration and widening
Diagnostic Tests. Brad Spring Director, Regulatory Affairs
Regulatory Challenges in the Development of Diagnostic Tests Industry Perspective Brad Spring Director, Regulatory Affairs September 28, 2011 Balancing Evidence of Safety & Effectiveness and Time to Market
Public-Private Partnerships for Bridging the Innovation Gap in Personalized Medicine
Public-Private Partnerships for Bridging the Innovation Gap in Personalized Medicine Martin LeBlanc, President and CEO, Caprion The 2014 ISPIM Americas Innovation Forum October 6, 2014 1 CHALLENGES FOR
CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD
CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this
BIOBANKING a challenge for public / private partnerships. Christian Bréchot
BIOBANKING a challenge for public / private partnerships Christian Bréchot Patient Disease Diagnosis Targeted Personalized therapies Risk medecine prediction Biomarker Diagnostic Theranostic: Efficay Toxicity
RESEARCH INVOLVING DATA AND/OR BIOLOGICAL SPECIMENS
RESEARCH INVOLVING DATA AND/OR BIOLOGICAL SPECIMENS 1. Overview IRB approval and participant informed consent are required to collect biological specimens for research purposes. Similarly, IRB approval
Assessing the Clinical Utility of Diagnostics Used in Drug Therapy
nature publishing group state Assessing the Clinical Utility of Diagnostics Used in Drug Therapy J Woodcock 1 There is an ongoing debate over the evidentiary standards that should be applied for introduction
In Vitro Diagnostic (IVD) Devices: How they Differ from Other Devices and How FDA Regulates Them
In Vitro Diagnostic (IVD) Devices: How they Differ from Other Devices and How FDA Regulates Them IRB Education Conference, Columbia University April 2007 Sally Hojvat, Ph.D. Director of Microbiology Devices
Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center
Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.
Regulatory Submission: Applying GLP in Surgical Efficacy Studies
Regulatory Submission: Applying GLP in Surgical Efficacy Studies Curtis Schondelmeyer, DVM Director Preclinical Veterinary Services and Efficacy and Surgical Research Services Welcome to Toxikon 2 CONFIDENTIAL
Pharmacology skills for drug discovery. Why is pharmacology important?
skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19th
CTC Technology Readiness Levels
CTC Technology Readiness Levels Readiness: Software Development (Adapted from CECOM s Software Technology Readiness Levels) Level 1: Basic principles observed and reported. Lowest level of software readiness.
STATE OF MICHIGAN DEPARTMENT OF INSURANCE AND FINANCIAL SERVICES Before the Director of Insurance and Financial Services
STATE OF MICHIGAN DEPARTMENT OF INSURANCE AND FINANCIAL SERVICES Before the Director of Insurance and Financial Services In the matter of: Petitioner, v Blue Care Network of Michigan, Respondent. File
Ask Us About Clinical Trials
Ask Us About Clinical Trials Clinical Trials and You. Our specialists and researchers are at the forefront of their fields and are leading the way in developing new therapies and procedures for diagnosing
Clinical Trial Designs for Incorporating Multiple Biomarkers in Combination Studies with Targeted Agents
Clinical Trial Designs for Incorporating Multiple Biomarkers in Combination Studies with Targeted Agents J. Jack Lee, Ph.D. Department of Biostatistics 3 Primary Goals for Clinical Trials Test safety and
Overview of FDA Compliance for Medical Devices
Glisland Training Series: Overview of FDA Compliance for Medical Devices Glisland, Inc. San Jose, California, USA http://www.glisland.com Description This course provides a concise overview of how FDA
Draft Guidance for Industry, Food and Drug Administration Staff, and Clinical Laboratories
14 1 2 3 4 5 6 7 8 9 10 11 12 13 15 16 17 18 19 20 21 22 23 24 25 26 27 Draft Guidance for Industry, Food and Drug Administration Staff, and Clinical Laboratories Framework for Regulatory Oversight of
MOBILE MEDICAL APPLICATIONS
October 7, 2013 EVOKE HEALTH POINT OF VIEW MOBILE MEDICAL APPLICATIONS FDA GUIDANCE FOR INDUSTRY FOR MORE INFORMATION: Mark McConaghy, VP, Strategy Evoke Health 267.765.4998 mark.mcconaghy@evokehealth.com
The Value of A Qualified Outcome Measure Janet Woodcock, M.D.
The Value of A Qualified Outcome Measure Janet Woodcock, M.D. The Critical Path Institute (CPI) Multiple Sclerosis Outcome Assessments Consortium (MSAOC) 1 April 2013 White Oak 1 Overview of Workshop Create
Participating in Alzheimer s Disease Clinical Trials and Studies
Participating in Alzheimer s Disease Clinical Trials and Studies FACT SHEET When Margaret was diagnosed with earlystage Alzheimer s disease at age 68, she wanted to do everything possible to combat the
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE E15
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE DEFINITIONS FOR GENOMIC BIOMARKERS, PHARMACOGENOMICS,
Accelerating Development and Approval of Targeted Cancer Therapies
Accelerating Development and Approval of Targeted Cancer Therapies Anna Barker, NCI David Epstein, Novartis Oncology Stephen Friend, Sage Bionetworks Cindy Geoghegan, Patient and Partners David Kessler,
Guidance for Clinical Investigators, Sponsors, and IRBs
Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs Improving Human Subject Protection U.S. Department of Health and Human Services Office of the Commissioner (OC) Center
IMPLEMENTING BIG DATA IN TODAY S HEALTH CARE PRAXIS: A CONUNDRUM TO PATIENTS, CAREGIVERS AND OTHER STAKEHOLDERS - WHAT IS THE VALUE AND WHO PAYS
IMPLEMENTING BIG DATA IN TODAY S HEALTH CARE PRAXIS: A CONUNDRUM TO PATIENTS, CAREGIVERS AND OTHER STAKEHOLDERS - WHAT IS THE VALUE AND WHO PAYS 29 OCTOBER 2015 DR. DIRK J. EVERS BACKGROUND TreatmentMAP
Guidance for Sponsors, Investigators, and Institutional Review Boards. Questions and Answers on Informed Consent Elements, 21 CFR 50.
Guidance for Sponsors, Investigators, and Institutional Review Boards Questions and Answers on Informed Consent Elements, 21 CFR 50.25(c) (Small Entity Compliance Guide) U.S. Department of Health and Human
EMA and Progressive Multifocal Leukoencephalopathy.
EMA and Progressive Multifocal Leukoencephalopathy. ENCePP Plenary, London 23 November 2011 Presented by: Henry Fitt Head of Coordination & Networking, Pharmacovigilance & Risk Management An agency of
Implementation of Pharmacogenomics in Clinical Practice: Barriers and Potential Solutions
Molecular Pathology : Principles in Clinical Practice Implementation of Pharmacogenomics in Clinical Practice: Barriers and Potential Solutions KT Jerry Yeo, Ph.D. University of Chicago Email: jyeo@bsd.uchicago.edu
Phenomenome Discoveries. Cutting Edge Disease Prevention Research 1
Cutting Edge Disease Prevention Research 1 Phenomenome Discoveries Inc. Phenomenome Discoveries Inc (PDI) is a life science company focused on the discovery and development of simple blood chemistry tests
Clinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute
Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,
National Cancer Institute
National Cancer Institute Taking Part in Cancer Treatment Research Studies U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Taking Part in Cancer Treatment Research Studies If
How Public-Private Partnerships Benefit All Stakeholders Douglas C. Throckmorton, MD Deputy Director for Regulatory Programs, CDER, FDA
How Public-Private Partnerships Benefit All Stakeholders Douglas C. Throckmorton, MD Deputy Director for Regulatory Programs, CDER, FDA September 10, 2013 Outline Need for improved science in support of
Guidance for Industry and FDA Staff
Guidance for Industry and FDA Staff Qualification Process for Drug Development Tools U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective
Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective Office of Vaccines Research and Review Center for Biologics Evaluation and Research U.S. Food
FDA Regulation of Whole Slide Imaging (WSI) Devices: Current Thoughts
FDA Regulation of Whole Slide Imaging (WSI) Devices: Current Thoughts Clinical Laboratory Improvement Advisory Committee Meeting Centers for Disease Control and Prevention February 15, 2012 Tremel A. Faison,
Mobile Medical Application Development: FDA Regulation
Mobile Medical Application Development: FDA Regulation Mobile Medical Applications: Current Environment Currently over 100,000 mobile health related applications are available for download; there is an
EXHIBIT COORDINATING PROVISIONS-STATE/FEDERAL LAW, ACCREDITATION STANDARDS AND GEOGRAPHIC EXCEPTIONS MARYLAND
EXHIBIT COORDINATING PROVISIONS-STATE/FEDERAL LAW, ACCREDITATION STANDARDS AND GEOGRAPHIC EXCEPTIONS MARYLAND I. INTRODUCTION: Scope. To the extent of any conflict between the Agreement and this State
Quality by Design Concept
3rd Jerusalem Conference on Quality and Pharma Sciences 6-7 June, 2012 QbD in Clinical Research - Where Can QbD Impact Clinical Research Practices? Dr. Yafit Stark Vice President, TEVA Pharmaceutical Industries,
Clarification of Human Subjects Research Definitions, Upcoming Changes in Research Processes
Clarification of Human Subjects Research Definitions, Upcoming Changes in Research Processes Introduction Clinical research (a type of Human Subjects Research activity) is a complex undertaking in which
SMF Awareness Seminar 2014
SMF Awareness Seminar 2014 Clinical Evaluation for In Vitro Diagnostic Medical Devices Dr Jiang Naxin Health Sciences Authority Medical Device Branch 1 In vitro diagnostic product means Definition of IVD
TIBCO Spotfire Helps Organon Bridge the Data Gap Between Basic Research and Clinical Trials
TIBCO Spotfire Helps Organon Bridge the Data Gap Between Basic Research and Clinical Trials Pharmaceutical leader deploys TIBCO Spotfire enterprise analytics platform across its drug discovery organization
General Considerations for Clinical Trial Design
General Considerations for Clinical Trial Design Steve Winitsky, M.D. Division of Clinical Evaluation and Pharmacology/Toxicology Office of Cellular, Tissue, and Gene Therapies Center for Biologics Evaluation
Guidance for Industry
Guidance for Industry Expanded Access to Investigational Drugs for Treatment Use Qs & As DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
Clinical Trials Glossary
Clinical Trials Glossary ADME: an acronym for absorption, distribution, metabolism and elimination. ADME studies determine how a drug is absorbed by the body, the chemical changes that it may undergo and
Next Generation Sequencing Informatics Markets
Next Generation Sequencing Informatics Markets Greg Caressi SVP Healthcare & Life Sciences November, 2014 Personalization, Communication, Decentralization, Collaboration From... One Size Fits All APPROACH...To
Memorandum. Factual Background
Memorandum TO: FROM: SUBJECT: Chris Ianelli and Jill Mullan, ispecimen, Inc. Kristen Rosati and Ana Christian, Polsinelli, PC ispecimen Regulatory Compliance DATE: January 26, 2014 You have asked us to
Genetic testing. The difference diagnostics can make. The British In Vitro Diagnostics Association
6 Genetic testing The difference diagnostics can make The British In Vitro Diagnostics Association Genetic INTRODUCTION testing The Department of Health published Our Inheritance, Our Future - Realising
Humanitarian Use Devices for Clinical Treatment or Diagnosis
Humanitarian Use Devices for Clinical Treatment or Diagnosis Content Applies To Mayo Clinic Human Research Protection Program Relying Organizations for which Mayo Clinic IRB is the IRB of Record Purpose
NIH/NCI Funding Opportunities for Cardio-Oncology Clinical Trials and Research Projects
NIH/NCI Funding Opportunities for Cardio-Oncology Clinical Trials and Research Projects Lori Minasian, M.D., FACP Deputy Director NCI Division of Cancer Prevention September 30, 2016 Outline Perspective
Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure
703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a
The Promise and Challenge of Adaptive Design in Oncology Trials
THE POWER OFx Experts. Experience. Execution. The Promise and Challenge of Adaptive Design in Oncology Trials Clinical oncology trials are more complex and time consuming than those in any other therapeutic
First In Human Pediatric Trials and Safety Assessment for Rare and Orphan Diseases
First In Human Pediatric Trials and Safety Assessment for Rare and Orphan Diseases Andrew E. Mulberg, MD, FAAP Division Deputy Director OND/ODE3/DGIEP FDA Partnership is the Key Coming together is a beginning;
TERM SHEET EXAMPLE. 1 P age
1 P age TERM SHEET EXAMPLE BIOTECHCO Overview & Business Strategy BIOTECHCO (the licensor), located in North Dakota, has a proprietary technology called ZIP that can generate fully human antibodies with
Ontario Public Drug Programs / Cancer Care Ontario Policy: Reimbursement of Publicly Funded Cancer Drugs within the Context of Clinical Trials
Ontario Public Drug Programs / Cancer Care Ontario Policy: Reimbursement of Publicly Funded Cancer Drugs within the Context of Clinical Trials Version: 2.0 Effective Date: January 29, 2016 Replaces Policy:
Essential Nursing Competencies and Curricula Guidelines for Genetics and Genomics: Outcome Indicators
Essential Nursing Competencies and Curricula Guidelines for Genetics and Genomics: Outcome Indicators Introduction The Outcome Indicators are an adjunct to the Essential Nursing Competencies and Curricula
From The Lab To Your Medicine Cabinet:
From The Lab To Your Medicine Cabinet: A Pharmaceutical Drug s Journey Presented by: Dr. Steven Hansel Sr. Director; Pfizer Moderated by: Sam Gilchrist Ph.D. Candidate; UBC The Drug Development Process
How Can Institutions Foster OMICS Research While Protecting Patients?
IOM Workshop on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials How Can Institutions Foster OMICS Research While Protecting Patients? E. Albert Reece, MD, PhD, MBA Vice
Proposed Definition for Clinical Decision Support Software
May 15, 2013 Proposed Definition for Clinical Decision Support Software The International Medical Device Regulators Forum (IMDRF) has recently announced a Work Item on Standalone Software. As we understand
Protecting Phase I Subjects IRB Considerations for Phase I Review of Research June 5, 2013
Webinar Series Protecting Phase I Subjects IRB Considerations for Phase I Review of Research June 5, 2013 Presented by: Julie Blasingim Director of Operations, Clinical Pharmacology About Schulman Associates
Kentucky Lung Cancer Research Program. 2010 Strategic Plan Update
Kentucky Lung Cancer Research Program 2010 Strategic Plan Update Approved by the KLCR Program Governance Board August 12, 2009 KLCR Program Strategic Plan Table of Contents Introduction... 3 GOAL 1: Investigator-Initiated
Technology funding opportunities at the National Cancer Institute
Technology funding opportunities at the National Cancer Institute Through the Cancer Diagnosis Program http://cancerdiagnosis.nci.nih.gov/index.html Avraham Rasooly Ph.D. National Cancer Institute, Cancer
IRB Process & Medical Devices. Sandra Rogers IRB Pacific University
+ IRB Process & Medical Devices Sandra Rogers IRB Pacific University + IRB Review of Research: Criteria n Informed Consent (Respect for Persons) n Will be sought prospectively n Includes required elements
What Lies Ahead? Trends to Watch: Health Care Product Development in North America
What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? for 2015 DIA has released its third annual What Lies Ahead? report, providing experts insights into the
BIOTECHNOLOGY OPERATIONS
BIOTECHNOLOGY OPERATIONS Principles and Practices Michael J. Roy TECHNISCHE INFORMATION SBIBLIOTHEK UNIVERSITATSBIBLIOTHEK HANNOVER CRC Press TaylorStFrancis Croup Boca Raton London New York CRC Press
2017 Request for Proposals Translational Product Development Fund (TPDF) Details and Instructions for Faculty
2017 Request for Proposals Translational Product Development Fund (TPDF) Details and Instructions for Faculty Awards Description and Criteria: The Mayo Clinic Center for Clinical and Translational Science
Guidance for Industry
Guidance for Industry End-of-Phase 2A Meetings U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 Procedural Guidance
US Perspective on the Regulatory Assessment of Benefit-Risk of Vaccines
US Perspective on the Regulatory Assessment of Benefit-Risk of Vaccines Norman W. Baylor Biologics Consulting Group, Inc. 23-25 June 2014 Foundation Merieux Conference Center OUTLINE OF PRESENTATION Introduction
SMALL BUSINESS INNOVATION RESEARCH (SBIR) SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) GRANT APPLICATIONS
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES PHS 2015-2 OMNIBUS SOLICITATION OF THE NATIONAL INSTITUTES OF HEALTH, CENTERS FOR DISEASE CONTROL AND PREVENTION, FOOD AND DRUG ADMINISTRATION, AND ADMINISTRATION
Clinical Trials: The Crux of Cancer Innovation
Clinical Trials: The Crux of Cancer Innovation Even as medical science is transforming cancer care, major deficiencies in the way cancer clinical trials are designed, carried out, regulated and funded
Introductory overview of medicines development process. Markku Toivonen
Introductory overview of medicines development process Markku Toivonen June 2014 Contents What is medical research? Evidence-based medicine Life cycle of drug development WHAT IS MEDICAL RESEARCH? How
Guidance for Industry
Guidance for Industry Codevelopment of Two or More New Investigational Drugs for Use in Combination U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
Expanded Access Programs. Richard Klein Office of Special Health issues Food and Drug Administration
Expanded Access Programs Richard Klein Office of Special Health issues Food and Drug Administration Expanded Access Programs (EAPs) What is expanded access? History Legislative background General principles
Clinical Trials: Questions and Answers
Clinical Trials: Questions and Answers Key Points Clinical trials are research studies that test how well new medical approaches work in people (see Question 1). Every clinical trial has a protocol, which
Personalized Predictive Medicine and Genomic Clinical Trials
Personalized Predictive Medicine and Genomic Clinical Trials Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute http://brb.nci.nih.gov brb.nci.nih.gov Powerpoint presentations
Glossary of Clinical Trial Terms
Glossary of Clinical Trial Terms ADVERSE REACTION: (Adverse Event): Also known as side effects, adverse reactions include any undesired actions or effects of the experimental drug or treatment. Experimental
Use of Electronic Health Record Data in Clinical Investigations
Use of Electronic Health Record Data in Clinical Investigations Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding